The interim results from PrimeC’s NST002 clinical trial indicated that treatment with PrimeC slowed disease progression in ALS patients, which highlights the exciting potential of this novel drug. The results were analysed using ALSFRS-R and vital capacity parameters. The 12-month study has monitored 15 patients with ALS over a period of 6 months and, in light of these promising results, is on track to continue for another 6 months. Additionally, Alon Ben-Noon announced that the company intends to initiate a double-blind clinical trial in 2021 to test the final combination of PrimeC.
Menu
Menu
